Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-11-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

DRUG

RT001

RT001

DRUG

RT001

RT001

DRUG

RT001

RT001

DRUG

RT001

RT001

OTHER

Vehicle Comparator

Vehicle Comparator

Sponsors & Collaborators

  • Revance Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888914 on ClinicalTrials.gov